3 completed, 1 active not recruiting, 1 recruiting, 1 unknown. 6 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 6 | Completed 3, Active not recruiting 1, Recruiting 1, Unknown 1 |
| Phase 2 | 1 | Active not recruiting 1 |
Follow Tuberculosis Infection: new trials by email Literature Review of Tuberculosis Infection trials Research Report on Tuberculosis Infection
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pharmacokinetics of Antituberculosis Drugs in Breastfeeding Women Standard dose rifampicin, High dose rifampicin, Standard dose isoniazid - Tuberculosis Infection, Healthy Volunteer | Phase 1 | Completed | McGill University Health Centre/Research Institute of the McGill University Health Centre | 60 | 2026-06-01 | 2026-11-02 |
| Safety and Tolerability of 1 Month Daily (1HP) and 3 Months Weekly (3HP) Isoniazid and Rifapentine With Pharmacokinetics of Dolutegravir (DTG) in Pregnant People With HIV Rifapentine, Isoniazid - HIV Seropositivity, Pregnancy | Phase 1 / Phase 2 | Active not recruiting | The Aurum Institute NPC | 252 | 2024-01-17 | 2025-12-12 |
| Dolutegravir Pharmacokinetics Among HIV/TB Coinfected Children Receiving Standard and High-dose Rifampicin rifampicin - Pediatric HIV Infection, Tuberculosis Infection | Phase 1 | Recruiting | Brigham and Women's Hospital | 20 | 2023-07-07 | 2026-07-30 |
| Evaluation of ТВ/Flu-05Е Vaccine for the Prevention of Tuberculosis Infection in BCG-vaccinated Volunteers Aged 18-50 Years TB/Flu-05E vaccine, Placebo - Tuberculosis Infection | Phase 1 | Completed | Tatyana Zubkova | 51 | 2023-05-10 | 2024-04-18 |
| Point-of-care Pharmacogenomic Testing to Optimize Isoniazid Dosing for Tuberculosis Prevention Low-dose isoniazid, Standard dose of isoniazid, High-dose isoniazid - Tuberculosis Infection, Isoniazid Adverse Reaction | Phase 1 | Completed | Stanford University | 78 | 2023-03-23 | 2026-06-15 |
| Safety and Tolerability of Chlorquine in Addition to Anti-tuberculosis Therapy Nivaquine ® (Chloroquine) - Tuberculosis Infection | Phase 1 | Unknown | University of Zurich | 16 | 2022-01-04 | 2024-07-01 |
Latent Tuberculosis (6) · Breast Feeding (1) · HIV Seropositivity (1)
Actinomycetales Infections (6) · Bacterial Infections (6) · Bacterial Infections and Mycoses (6) · Gram-Positive Bacterial Infections (6) · Infections (6) · Latent Infection (6) · Mycobacterium Infections (6) · Tuberculosis (6) · Behavior (1) · Blood-Borne Infections (1) · Communicable Diseases (1) · Feeding Behavior (1) · Genital Diseases (1) · HIV Infections (1) · Immune System Diseases (1)
Isoniazid (4) · Rifampin (3) · rifapentine (2) · Chloroquine (1) · Ethambutol (1) · Levofloxacin (1) · Pyrazinamide (1) · bedaquiline (1)
Brigham and Women's Hospital (1) · McGill University Health Centre/Research Institute of the McGill University Health Centre (1) · Stanford University (1) · Tatyana Zubkova (1) · The Aurum Institute NPC (1) · University of Zurich (1)
Brazil (1) · Indonesia (1) · Nigeria (1) · Russia (1) · South Africa (1) · Switzerland (1)
Dick Menzies, MD (1) · Dr Vaneshree Govender (1) · Holly Rawizza, MD, MPH (1) · Jason R Andrews, MD (1) · Marisa Kaelin, Dr. med. (1)
R21AI172182 (1)